US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MetaVia Inc

1.50

+0.8041115.55%

Post-market: 1.41-0.0899-5.99%19:59 EDT

Volume:90.30M

Turnover:119.19M

Market Cap:36.30M

PE:-0.93

High:1.73

Open:0.6870

Low:0.6818

Close:0.6959

52wk High:3.82

52wk Low:0.5555

Shares:24.20M

Float Shares:9.22M

Volume Ratio:2,212.66

T/O Rate:979.44%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6069

EPS(LYR):-3.5570

ROE:-129.46%

ROA:-53.04%

PB:3.77

PE(LYR):-0.42

Loading ...

Overview Company News Filings

Metavia Inc : H.c. Wainwright Assumes Coverage With Buy Rating; Target Price $12

THOMSON REUTERS

MetaVia Inc reports results for the quarter ended June 30 - Earnings Summary

MetaVia Inc expected to post a loss of 32 cents a share - Earnings Preview

Metavia Inc. Unveils New Presentation Highlighting Advances in Cardiometabolic Disease Therapies

Metavia Reports Second Quarter 2025 Financial Results And Provides Corporate Update

MetaVia Q2 EPS $(0.26) Beats $(0.31) Estimate

Metavia Inc. Reports Q2 2025 Results: Net Loss Narrows to $4M, EPS Improves to $0.26 from $1.85 Year-Over-Year

Metavia Inc - Qtrly Shr Loss $0.26

THOMSON REUTERS

BRIEF-Metavia Extends 48 Mg MAD Portion Of Its Phase 1 Clinical Trial Of Da-1726 For Treatment Of Obesity

MetaVia Inc. Announces Extension of Phase 1 Clinical Trial for Obesity Treatment DA-1726, Top-Line Data Expected Q4 2025

Metavia Extends 48 Mg Mad Portion of Its Phase 1 Clinical Trial of Da-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

THOMSON REUTERS

Metavia Inc - Top-Line Data Expected in Q4 2025

THOMSON REUTERS

BRIEF-Metavia Announces Ai-Driven Collaboration With Syntekabio To Explore Additional Indications For Da-1241

MetaVia Inc. Partners with Syntekabio to Enhance DA-1241's Therapeutic Potential Using AI Technology

Metavia Announces AI-Driven Collaboration With Syntekabio to Explore Additional Indications for Da-1241

THOMSON REUTERS

Metavia Inc. Doses First Patient in 48 mg Cohort of Phase 1 Trial for Obesity Drug DA-1726, Top-Line Data Expected by End of 2025

Metavia Files Prospectus for Investors to Sell 14.1 Million Shares

MT Newswires Live

BRIEF-Metavia Files For Resale Of Up To 14.1 Million Shares Of Common Stock By Selling Securityholders

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MTVA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MTVA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTVA\",,,,,undefined,":{"symbol":"MTVA","market":"US","secType":"STK","nameCN":"MetaVia Inc","latestPrice":1.5,"timestamp":1757966400000,"preClose":0.6959,"halted":0,"volume":90297226,"hourTrading":{"tag":"盘后","latestPrice":1.4101,"preClose":1.5,"latestTime":"19:59 EDT","volume":7236082,"amount":10000158.1392,"timestamp":1757980799171},"delay":0,"floatShares":9219300,"shares":24197809,"eps":-1.606876,"marketStatus":"Closed","change":0.8041,"latestTime":"09-15 16:00:00 EDT","open":0.687,"high":1.7299,"low":0.6818,"amount":119185150.6608104,"amplitude":1.506107,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.606876,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1758009600000},"marketStatusCode":5,"adr":0,"listingDate":1470369600000,"exchange":"NASDAQ","adjPreClose":0.6959,"preHourTrading":{"tag":"盘前","latestPrice":0.72,"preClose":0.6959,"latestTime":"09:05 EDT","volume":55,"amount":39.6,"timestamp":1757941503551},"postHourTrading":{"tag":"盘后","latestPrice":1.4101,"preClose":1.5,"latestTime":"19:59 EDT","volume":7236082,"amount":10000158.1392,"timestamp":1757980799171},"volumeRatio":2212.657529},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTVA\",,,,,undefined,":{"symbol":"MTVA","floatShares":9219300,"roa":"-53.04%","roe":"-129.46%","lyrEps":-3.556986,"volumeRatio":2212.657529,"shares":24197809,"dividePrice":0,"high":1.7299,"amplitude":1.506107,"preClose":0.6959,"low":0.6818,"week52Low":0.5555,"pbRate":"3.77","week52High":3.823,"institutionHeld":0,"latestPrice":1.5,"eps":-1.606876,"divideRate":0,"volume":90297226,"delay":0,"ttmEps":-1.606876,"open":0.687,"prevYearClose":2.03,"prevWeekClose":0.6959,"prevMonthClose":0.6342,"prevQuarterClose":0.6432,"fiveDayClose":0.6901,"twentyDayClose":0.64,"sixtyDayClose":0.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MTVA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-07","symbol":"MTVA","fiscalQuarterEnding":"2025/06","expectedEps":-0.32,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.26},{"market":"US","date":"2025-05-14","symbol":"MTVA","fiscalQuarterEnding":"2025/03","expectedEps":-0.57,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.36},{"date":"2025-03-20","symbol":"MTVA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742457600000,"name":null,"time":"Pre-Market","dateTimestamp":1742443200000,"actualEps":null},{"market":"US","date":"2024-11-07","symbol":"MTVA","fiscalQuarterEnding":"2024/09","expectedEps":-0.82,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.55},{"market":"US","date":"2024-08-14","symbol":"MTVA","fiscalQuarterEnding":"2024/06","expectedEps":-1.38,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"pre","actualEps":-1.85}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MTVA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MTVA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1735617600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MTVA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MTVA","date":"2025-09-12","current":-0.894708,"percent":0.015464,"low":-0.903083,"twenty":-0.675347,"median":-0.537746,"eighty":-0.459434,"high":-0.203888,"avg":-0.546056,"sd":0.172926,"marketCap":16544042},"quantilePoints":[{"date":"2024-12-06","current":-0.714557,"twenty":-0.800304,"median":-0.792227,"eighty":-0.751814,"marketCap":19816823},{"date":"2024-12-13","current":-0.716111,"twenty":-0.79347,"median":-0.728538,"eighty":-0.7158,"marketCap":19859903},{"date":"2024-12-20","current":-0.546792,"twenty":-0.767348,"median":-0.716111,"eighty":-0.685354,"marketCap":15164177},{"date":"2024-12-27","current":-0.562326,"twenty":-0.746234,"median":-0.70213,"eighty":-0.556112,"marketCap":15594978},{"date":"2025-01-03","current":-0.655529,"twenty":-0.730091,"median":-0.686597,"eighty":-0.553006,"marketCap":18179781},{"date":"2025-01-10","current":-0.661742,"twenty":-0.733198,"median":-0.686597,"eighty":-0.564811,"marketCap":18352101},{"date":"2025-01-17","current":-0.58718,"twenty":-0.720771,"median":-0.663296,"eighty":-0.577238,"marketCap":16284258},{"date":"2025-01-24","current":-0.602714,"twenty":-0.720771,"median":-0.647762,"eighty":-0.584073,"marketCap":16715059},{"date":"2025-01-31","current":-0.584073,"twenty":-0.717664,"median":-0.630675,"eighty":-0.584073,"marketCap":16198098},{"date":"2025-02-07","current":-0.562326,"twenty":-0.716111,"median":-0.615141,"eighty":-0.562326,"marketCap":15594978},{"date":"2025-02-14","current":-0.512617,"twenty":-0.714557,"median":-0.608927,"eighty":-0.546792,"marketCap":14216416},{"date":"2025-02-21","current":-0.509511,"twenty":-0.704615,"median":-0.602714,"eighty":-0.540578,"marketCap":14130256},{"date":"2025-02-28","current":-0.453589,"twenty":-0.699297,"median":-0.58718,"eighty":-0.518583,"marketCap":12579374},{"date":"2025-03-07","current":-0.487763,"twenty":-0.688995,"median":-0.584073,"eighty":-0.503297,"marketCap":13527135},{"date":"2025-03-14","current":-0.467569,"twenty":-0.681626,"median":-0.568539,"eighty":-0.495468,"marketCap":12967095},{"date":"2025-03-21","current":-0.48401,"twenty":-0.667956,"median":-0.562326,"eighty":-0.487763,"marketCap":13354815},{"date":"2025-03-28","current":-0.48933,"twenty":-0.662363,"median":-0.546792,"eighty":-0.487763,"marketCap":13501595},{"date":"2025-04-04","current":-0.47992,"twenty":-0.656772,"median":-0.540578,"eighty":-0.485083,"marketCap":13241949},{"date":"2025-04-11","current":-0.429732,"twenty":-0.643102,"median":-0.539025,"eighty":-0.482756,"marketCap":11857170},{"date":"2025-04-17","current":-0.23033,"twenty":-0.636267,"median":-0.537471,"eighty":-0.476844,"marketCap":6355270},{"date":"2025-04-25","current":-0.266622,"twenty":-0.631917,"median":-0.512617,"eighty":-0.463425,"marketCap":7356638},{"date":"2025-05-02","current":-0.239019,"twenty":-0.626947,"median":-0.506404,"eighty":-0.454331,"marketCap":6595010},{"date":"2025-05-09","current":-0.222708,"twenty":-0.618869,"median":-0.49874,"eighty":-0.452346,"marketCap":6144956},{"date":"2025-05-16","current":-0.238257,"twenty":-0.615141,"median":-0.497083,"eighty":-0.429105,"marketCap":5848960},{"date":"2025-05-23","current":-0.285534,"twenty":-0.611413,"median":-0.49458,"eighty":-0.263184,"marketCap":7009578},{"date":"2025-05-30","current":-0.543676,"twenty":-0.612655,"median":-0.49689,"eighty":-0.271352,"marketCap":13346706},{"date":"2025-06-06","current":-0.549972,"twenty":-0.608927,"median":-0.497673,"eighty":-0.281282,"marketCap":13501264},{"date":"2025-06-13","current":-0.597709,"twenty":-0.608927,"median":-0.503297,"eighty":-0.294785,"marketCap":14673160},{"date":"2025-06-20","current":-0.557862,"twenty":-0.607995,"median":-0.509511,"eighty":-0.332562,"marketCap":13694949},{"date":"2025-06-27","current":-0.542591,"twenty":-0.603956,"median":-0.515396,"eighty":-0.428478,"marketCap":13320078},{"date":"2025-07-03","current":-0.516978,"twenty":-0.602714,"median":-0.515103,"eighty":-0.429732,"marketCap":12691292},{"date":"2025-07-11","current":-0.572913,"twenty":-0.599701,"median":-0.516978,"eighty":-0.432869,"marketCap":14064436},{"date":"2025-07-18","current":-0.535431,"twenty":-0.597709,"median":-0.518414,"eighty":-0.439456,"marketCap":13144307},{"date":"2025-07-25","current":-0.587857,"twenty":-0.5965,"median":-0.521601,"eighty":-0.450482,"marketCap":14431313},{"date":"2025-08-01","current":-0.482926,"twenty":-0.587857,"median":-0.520838,"eighty":-0.453589,"marketCap":11855342},{"date":"2025-08-08","current":-0.674088,"twenty":-0.587857,"median":-0.518654,"eighty":-0.453589,"marketCap":12464564},{"date":"2025-08-15","current":-0.837521,"twenty":-0.602714,"median":-0.525504,"eighty":-0.453589,"marketCap":15486597},{"date":"2025-08-22","current":-0.836212,"twenty":-0.615141,"median":-0.534692,"eighty":-0.453589,"marketCap":15462399},{"date":"2025-08-29","current":-0.846681,"twenty":-0.624461,"median":-0.53558,"eighty":-0.454826,"marketCap":15655982},{"date":"2025-09-05","current":-0.898895,"twenty":-0.643102,"median":-0.537471,"eighty":-0.457336,"marketCap":16621475},{"date":"2025-09-12","current":-0.894708,"twenty":-0.675347,"median":-0.537746,"eighty":-0.459434,"marketCap":16544042}],"updateTime":1757956919086},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MTVA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2564373499","title":"Metavia Inc : H.c. Wainwright Assumes Coverage With Buy Rating; Target Price $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2564373499","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564373499?lang=en_us&edition=fundamental","pubTime":"2025-09-04 18:19","pubTimestamp":1756981173,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nFWN3UR0DK:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2558647436","title":"MetaVia Inc reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2558647436","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558647436?lang=en_us&edition=fundamental","pubTime":"2025-08-12 21:30","pubTimestamp":1755005451,"startTime":"0","endTime":"0","summary":"MetaVia Inc reports results for the quarter ended June 30 - Earnings SummaryMetaVia Inc MTVA.OQ reported a quarterly adjusted loss of 26 cents per share for the quarter ended June 30, higher than the ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nL8N3U4122:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2558441579","title":"MetaVia Inc  expected to post a loss of 32 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2558441579","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558441579?lang=en_us&edition=fundamental","pubTime":"2025-08-09 02:00","pubTimestamp":1754676027,"startTime":"0","endTime":"0","summary":"MetaVia Inc  expected to post a loss of32cents a share - Earnings Preview MetaVia Inc MTVA.OQ MTVA.O is expected to  show no change in quarterly revenue when it reports  results on November 5 (estimat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nL8N3U037U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2557591304","title":"Metavia Inc. Unveils New Presentation Highlighting Advances in Cardiometabolic Disease Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2557591304","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557591304?lang=en_us&edition=fundamental","pubTime":"2025-08-08 04:44","pubTimestamp":1754599486,"startTime":"0","endTime":"0","summary":"Metavia Inc., a clinical-stage biotech company focused on cardiometabolic diseases, recently presented updates on their pipeline targeting obesity and MASH with next-generation therapeutics. Key highlights include the development of DA-1726, a novel GLP1R/GCGR dual agonist for obesity, which has shown no treatment-related discontinuations and mild gastrointestinal events in Phase 1 trials. The company also shared promising results from DA-1241 for MASH, which met its primary endpoint and demonstrated direct hepatic effects in Phase 2a trials. Metavia plans to pursue further studies and regulatory milestones in the coming years. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. M","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nNDL97snkm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2557156643","title":"Metavia Reports Second Quarter 2025 Financial Results And Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2557156643","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557156643?lang=en_us&edition=fundamental","pubTime":"2025-08-07 21:10","pubTimestamp":1754572256,"startTime":"0","endTime":"0","summary":"Aug 7 (Reuters) - MetaVia Inc ::*METAVIA REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE*METAVIA INC - QTRLY LOSS PER SHARE $0.26  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 07-AUG-202512:31:04.32 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nRSDXVr1Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2557634705","title":"MetaVia Q2 EPS $(0.26) Beats $(0.31) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2557634705","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557634705?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:34","pubTimestamp":1754570082,"startTime":"0","endTime":"0","summary":"MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 85.95 percent increase over losses of $(1.85) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/46960259/metavia-q2-eps-0-26-beats-0-31-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2557655015","title":"Metavia Inc. Reports Q2 2025 Results: Net Loss Narrows to $4M, EPS Improves to $0.26 from $1.85 Year-Over-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2557655015","media":"Reuters","labels":["dataReport","event","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557655015?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:31","pubTimestamp":1754569894,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire  on August 07, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nNDL9MCKTB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,event,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2557563463","title":"Metavia Inc - Qtrly Shr Loss $0.26","url":"https://stock-news.laohu8.com/highlight/detail?id=2557563463","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557563463?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:31","pubTimestamp":1754569864,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nTUABKQVPF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2557641377","title":"BRIEF-Metavia Extends 48 Mg MAD Portion Of Its Phase 1 Clinical Trial Of Da-1726 For Treatment Of Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2557641377","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557641377?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:51","pubTimestamp":1754484684,"startTime":"0","endTime":"0","summary":"BRIEF-Metavia Extends 48 Mg MAD Portion Of Its Phase 1 Clinical Trial Of Da-1726 For Treatment Of Obesity Aug 6 (Reuters) - MetaVia Inc MTVA.O:METAVIA EXTENDS 48 MG MAD PORTION OF ITS PHASE 1 CLINICAL","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nTUAFPQQY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2557437294","title":"MetaVia Inc. Announces Extension of Phase 1 Clinical Trial for Obesity Treatment DA-1726, Top-Line Data Expected Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2557437294","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557437294?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:31","pubTimestamp":1754483483,"startTime":"0","endTime":"0","summary":"MetaVia Inc. , a biotechnology company focused on cardiometabolic diseases, has announced an extension of its Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog agonist targeting obesity. The trial's 48 mg multiple ascending dose cohort has been extended to 8 weeks, with a fifth weekly dose administered to the first patient. This extension aims to assess early efficacy, safety, and patient tolerability with longer-term exposure, and explore the non-titrated maximum tolerated dose. Previously reported data from the 32 mg dose showed promising results in weight loss and waist reduction with favorable safety profiles. Top-line data from the extended trial is anticipated in the fourth quarter of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investme","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nNDL58HMgK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2557742713","title":"Metavia Extends 48 Mg Mad Portion of Its Phase 1 Clinical Trial of Da-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient","url":"https://stock-news.laohu8.com/highlight/detail?id=2557742713","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557742713?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:31","pubTimestamp":1754483462,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nTUAFPQQY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2557273374","title":"Metavia Inc - Top-Line Data Expected in Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2557273374","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557273374?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:31","pubTimestamp":1754483462,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nTUAFPQQY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2556384461","title":"BRIEF-Metavia Announces Ai-Driven Collaboration With Syntekabio To Explore Additional Indications For Da-1241","url":"https://stock-news.laohu8.com/highlight/detail?id=2556384461","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556384461?lang=en_us&edition=fundamental","pubTime":"2025-08-04 21:09","pubTimestamp":1754312944,"startTime":"0","endTime":"0","summary":"BRIEF-Metavia Announces Ai-Driven Collaboration With Syntekabio To Explore Additional Indications For Da-1241Aug 4 (Reuters) - SyntekaBio Inc 226330.KQ:METAVIA ANNOUNCES AI-DRIVEN COLLABORATION WITH S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nTUA1PYWF8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2556238143","title":"MetaVia Inc. Partners with Syntekabio to Enhance DA-1241's Therapeutic Potential Using AI Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2556238143","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556238143?lang=en_us&edition=fundamental","pubTime":"2025-08-04 20:31","pubTimestamp":1754310680,"startTime":"0","endTime":"0","summary":"MetaVia Inc. has announced a new partnership with Syntekabio, Inc., a leader in AI-driven drug discovery. This collaboration aims to explore additional indications for MetaVia's oral GPR119 agonist, DA-1241. By leveraging Syntekabio's DeepMatcher platform, the partnership will conduct extensive virtual screenings against over 1,700 validated protein targets. The goal is to identify new, high-potential indications for DA-1241, while ensuring specificity and minimizing off-target effects. This strategic collaboration builds on positive Phase 2a study results and seeks to maximize the therapeutic potential of DA-1241 across various unmet medical needs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original cont","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nNDL4q4g5r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2556199381","title":"Metavia Announces AI-Driven Collaboration With Syntekabio to Explore Additional Indications for Da-1241","url":"https://stock-news.laohu8.com/highlight/detail?id=2556199381","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556199381?lang=en_us&edition=fundamental","pubTime":"2025-08-04 20:31","pubTimestamp":1754310662,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nTUA1PYWF8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2550563712","title":"Metavia Inc. Doses First Patient in 48 mg Cohort of Phase 1 Trial for Obesity Drug DA-1726, Top-Line Data Expected by End of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2550563712","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550563712?lang=en_us&edition=fundamental","pubTime":"2025-07-09 20:31","pubTimestamp":1752064291,"startTime":"0","endTime":"0","summary":"Metavia Inc. Doses First Patient in 48 mg Cohort of Phase 1 Trial for Obesity Drug DA-1726, Top-Line Data Expected by End of 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire  on July 09, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nNDL3BNh1T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2548843324","title":"Metavia Files Prospectus for Investors to Sell 14.1 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2548843324","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548843324?lang=en_us&edition=fundamental","pubTime":"2025-07-03 05:50","pubTimestamp":1751493029,"startTime":"0","endTime":"0","summary":"Metavia (MTVA) late Wednesday filed a registration statement for its shareholders to resell up to about 14.1 million shares from time to time.The shares resulted from a private placement in May, according to the filing. Metavia will not receive any proceeds from the resale.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","MTVA","ISBC","BK4211"],"gpt_icon":0},{"id":"2548181778","title":"BRIEF-Metavia Files For Resale Of Up To 14.1 Million Shares Of Common Stock By Selling Securityholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2548181778","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548181778?lang=en_us&edition=fundamental","pubTime":"2025-07-03 04:11","pubTimestamp":1751487093,"startTime":"0","endTime":"0","summary":"BRIEF-Metavia Files For Resale Of Up To 14.1 Million Shares Of Common Stock By Selling SecurityholdersJuly 2 (Reuters) - MetaVia Inc MTVA.O:METAVIA INC FILES FOR RESALE OF UP TO 14.1 MILLION SHARES OF","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nFWN3SZ0MD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":51,"code":"91000000","status":"200"}]}}